Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (796)	4/24/2003 6:55:15 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

From VRTX 1Q PR: "As part of a broad strategy to develop pralnacasan for the treatment of multiple major inflammatory diseases, Aventis began a 400-patient Phase II proof-of-concept study of pralnacasan in osteoarthritis (OA) in January 2003. Today, Vertex reported that patient enrollment in this study has been recently completed. The objective of the study is to enable Aventis and Vertex to evaluate the safety and efficacy of pralnacasan as a novel, first-in-class treatment for OA. Pralnacasan is an orally administered inhibitor of interleukin-1 beta converting enzyme (ICE), an important enzyme regulating inflammatory processes." Normaly, REGN will wait until they complete PIII trial(s), and IF positive they will say: We have more potent candidate! Or maybe Novartis, with back door peak at VRTX lab, may start to think more positively? Miljenko